Hyperlipidaemia, Metabolic Syndrome
Conditions
Keywords
Olive oil, MLCT oil, plasma metabolome, gut microbiota
Brief summary
The type of cooking oil used is a crucial factor influencing dietary quality. The purpose of this study is to investigate the effects of olive oil and MLCT oil intervention on glucose and lipid homeostasis in patients with MetS.
Detailed description
We conducted a 6-month RCT to evaluate the effects of olive oil and MLCT as cooking oils on glucose and lipid homeostasis in patients with MetS; investigate the changes in lipoprotein subfractions and metabolites using NMR spectroscopy, alongside gut microbiota alterations, to elucidate potential mechanisms; and identify baseline variables associated with the anti-obesity effects of olive oil and MLCT.
Interventions
DIETARY_SUPPLEMENTOlive oil use
Olive oil, 25-30g/d by day for 6 month
DIETARY_SUPPLEMENTMLCT oil use
MLCT oil, 25-30g/d by day for 6 month
Sponsors
Zhejiang University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
40 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
Participants eligible for the study were those with a confirmed MetS diagnosis according to the IDF criteria53, aged between 40 and 70, and who reported infrequent consumption of meals outside the home (≤3 times per week)
Exclusion criteria
(i) current breastfeeding or pregnancy; (ii) history of cardiovascular disease, including heart disease, coronary artery disease, stroke, cerebral infarction, viral hepatitis (e.g., hepatitis A or B), chronic kidney disease (estimated glomerular filtration rate \[GFR\] \<60 ml/min), or malignancy; (iii) presence of diabetic ketoacidosis or hyperketonemia; (iv) recent alterations in prescribed medication within the previous 6 months; (v) current use of insulin therapy; (vi) consumption of MLCT in the preceding 6 months; (vii) participation in other clinical research studies within the last 6 months; and (viii) premenopausal women
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Body fat distribution and muscle conten from baseline | 6 month | The whole body of the patient was scanned and analyzed by a DXA (Prodigy Primo, Dalex-Ohmeda, Inc., USA) to measure the total and regional body fat mass (FM) and lean mass. |
| Change in body weight from baseline | 6 month | The investigators will measure body weight of participants before and after treatment. |
| Change in triglycerides from baseline | 6 month | The investigators will measure triglyceride levels in blood samples before and after treatment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in waist circumference from baseline | 6 month | The investigators will measure waist circumference of participants before and after treatment. |
| Change in blood metabolome | 6 month | The investigators will collect blood samples from every participant and the high-throughput NMR metabolomics platform will be used to analyze the blood metabolomics profile. |
| Change in MetS indicators from baseline | 6 month | The investigators will measure TC, LDL-C, HDL-C, and glucose levels in blood samples and blood pressure before and after treatment. |
| Change in gut microbiota from baseline | 6 month | The investigators will collect faeces sample from every participants and 16S rDNA sequencing will be used to analyze the composition of gut microbiota. |
Countries
China
Outcome results
None listed